Rhythm Pharmaceuticals Inc (STU:1RV)
€ 39.255 -0.74 (-1.85%) Market Cap: 2.43 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 42.35 GF Score: 52/100

Rhythm Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript

May 12, 2022 / 12:20AM GMT
Release Date Price: €3.44 (+7.50%)
Daniel Giraldo Perez
BofA Securities, Research Division - Associate

Thank you for joining us on the last session of day 2 of the Bank of America Healthcare Conference. My name is Daniel Giraldo. I'm one of the associates in the smidcap biotech team at BofA. And joining me today is David Meeker, CEO of RHythm Pharmaceuticals. Welcome David. Thank you for joining us today.

David P. Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President & CEO

Thank you, Daniel.

Questions & Answers

Daniel Giraldo Perez
BofA Securities, Research Division - Associate

So maybe we can start by you giving us a brief overview of the company and maybe highlight key catalysts coming up in the next 12 months?

David P. Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President & CEO

Yes. Sure. So Rhythm is a relatively small biotechnology company focused on rare genetic diseases of obesity. The -- we work on a pathway in the brain called the melanocortin-4 pathway, which

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot